Kalaris Therapeutics, Inc.
KLRS
$3.54
$0.164.73%
NASDAQ
| 03/31/2025 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.32M | 602.00K | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.35M | 2.56M | |||
| Operating Income | -10.35M | -2.56M | |||
| Income Before Tax | -10.20M | -3.41M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.20M | -3.41M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.20M | -3.41M | |||
| EBIT | -10.35M | -2.56M | |||
| EBITDA | -- | -- | |||
| EPS Basic | -2.52 | -2.60 | |||
| Normalized Basic EPS | -1.57 | -1.62 | |||
| EPS Diluted | -2.52 | -2.60 | |||
| Normalized Diluted EPS | -1.57 | -1.62 | |||
| Average Basic Shares Outstanding | 4.05M | 1.31M | |||
| Average Diluted Shares Outstanding | 4.05M | 1.31M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||